US approves Mylan's purchase of Strides unit, with conditions
WASHINGTON, Sept 26
WASHINGTON, Sept 26 (Reuters) - Generic drugmaker Mylan Inc has won U.S. antitrust approval, with conditions, to buy Agila, a unit of India's Strides Arcolab Ltd, the Federal Trade Commission said on Thursday.
The companies will have to divest 11 generic injectable drugs as a condition of approving the deal, the FTC said.
The deal was valued at $1.6 billion when it was announced in February.